Last reviewed · How we verify
Polyarticular Juvenile Idiopathic Arthritis
Approved treatments
- In open-label phase: treatment with tofacitinib · Pfizer
- Tasocitinib · Pfizer
- Xeljanz · Pfizer
Tofacitinib is a JAK inhibitor that prevents phosphorylation and activation of STATs. - Simponi · Centocor Ortho Biotech Inc
Simponi works by binding to tumor necrosis factor, preventing it from interacting with its receptors and thereby reducing inflammation. - tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- Xeljanz · Pfizer
Tofacitinib inhibits Janus kinase enzymes to prevent STAT phosphorylation and activation. - Simponi · Alvotech Swiss AG
- TOFA
Clinical guidelines
- FDA label — 2L
XELJANZ (tablets and oral solution) are indicated for the treatment of pediatric patients 2 years of age and older with active polyarticular course juvenile idiopathic arthritis (pcJIA), who have had an inadequate response or intolerance to one or more TNF blockers. - FDA label — 2L
XELJANZ (tablets and oral solution) are indicated for the treatment of pediatric patients 2 years of age and older with active polyarticular course juvenile idiopathic arthritis (pcJIA), who have had an inadequate response or intolerance to one or more TNF blockers. - FDA label — 2L
XELJANZ (tablets and oral solution) are indicated for the treatment of pediatric patients 2 years of age and older with active polyarticular course juvenile idiopathic arthritis (pcJIA), who have had an inadequate response or intolerance to one or more TNF blockers. - FDA label — any
ORENCIA is indicated for the treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA). - FDA label — any
ORENCIA is indicated for the treatment of patients 2 years of age and older with active psoriatic arthritis (PsA).
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Polyarticular Juvenile Idiopathic Arthritis patent landscape — cliff calendar, originator estates, attackable patents
- Polyarticular Juvenile Idiopathic Arthritis treatment landscape brief
- Polyarticular Juvenile Idiopathic Arthritis treatment updates RSS
Frequently asked questions about Polyarticular Juvenile Idiopathic Arthritis
What drugs treat Polyarticular Juvenile Idiopathic Arthritis?
Tracked treatments include In open-label phase: treatment with tofacitinib, Tasocitinib, Xeljanz, Simponi, tocilizumab or sarilumab, TOFA.
What is the treatment for Polyarticular Juvenile Idiopathic Arthritis?
Standard treatment for Polyarticular Juvenile Idiopathic Arthritis includes In open-label phase: treatment with tofacitinib, Tasocitinib, Xeljanz, Simponi, tocilizumab or sarilumab. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Polyarticular Juvenile Idiopathic Arthritis?
FDA label publishes guidelines for Polyarticular Juvenile Idiopathic Arthritis. 5 guideline references tracked.
Related
- Treatment landscape: Polyarticular Juvenile Idiopathic Arthritis patent cliff · Polyarticular Juvenile Idiopathic Arthritis CI report
- Treatment: In open-label phase: treatment with tofacitinib · Pfizer
- Treatment: Tasocitinib · Pfizer
- Treatment: Xeljanz · Pfizer
- Treatment: Simponi · Centocor Ortho Biotech Inc
- Treatment: tocilizumab or sarilumab · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing